micro-community-banner
 
  • Saved
case study

Patient Background: An 82-year-old woman with severe symptomatic aortic stenosis was evaluated for transcatheter aortic valve replacement (TAVR). Her baseline electrocardiogram (ECG) showed right bundle branch block (RBBB) and a prolonged QRS duration.

Assessment and Diagnosis: She underwent TAVR. Her baseline right bundle branch block (RBBB; adjusted odds ratio [ORadj], 2.49) and each 1-millisecond increase in QRS duration (ORadj, 1.01) were identified as independent predictors of permanent pacemaker implantation (PPI).

Clinical Outcome: Approximately 21.5% of patients undergoing TAVR require PPI, most commonly due to third-degree atrioventricular (AV) block (46.4%).

Suggested Treatment Plan: When PPI is necessary, physiological pacing techniques—such as His-bundle or left bundle branch pacing—should be considered to minimize electromechanical dyssynchrony.

Patient Education: Patients should be counseled on the increased risk of PPI after TAVR and its association with higher long-term mortality.

Follow-up: Ongoing follow-up is essential. PPI is an independent predictor of mortality, with an estimated 7-year mortality of 43.3% in PPI recipients versus 30.9% in those without PPI.

  1. What ECG markers help predict pacemaker need post-TAVR? Answer Baseline right bundle branch block and increased QRS duration are key predictors. Prosthetic valve type, particularly self-expanding designs, also influences pacemaker need.
  2. What pacing strategies can reduce long-term mortality after TAVR? Answer His-bundle or left bundle branch pacing helps reduce dyssynchrony. In low-dependency cases, AV conduction algorithms are useful. Leadless pacing is promising but needs more data.
  • Saved
Contributions of Inflammation to Cardiometabolic Heart Failure with Preserved Ejection Fraction - PubMed

Contributions of Inflammation to Cardiometabolic Heart Failure with Preserved Ejection Fraction - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39357068/

The most common form of heart failure is heart failure with preserved ejection fraction (HFpEF). While heterogeneous in origin, the most common form of HFpEF is the cardiometabolic manifestation. Obesity...

This review explores how obesity- and age-driven inflammation contribute to HFpEF pathophysiology, emphasizing immune-metabolic interactions and highlighting targeted therapeutic pathways beyond broad anti-inflammatory strategies.

  • Saved
Heart failure, inflammation and exercise - PubMed

Heart failure, inflammation and exercise - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/40520009/

Heart failure (HF) is a condition characterized by high morbidity, mortality, and a substantial healthcare burden, in which inflammation plays a pivotal role. This review provides a comprehensive overview of...

 

Inflammation drives heart failure progression. This review explores immune cell roles, signaling pathways, biomarkers, and highlights exercise as a promising anti-inflammatory intervention to improve cardiac function and personalize treatment.

  • Saved
Stress echocardiography in heart failure patients: additive value and caveats - PubMed

Stress echocardiography in heart failure patients: additive value and caveats - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39060836/

Heart failure (HF) is a clinical syndrome characterized by well-defined signs and symptoms due to structural and/or myocardial functional impairment, resulting in raised intracardiac pressures and/or inadequate cardiac stroke volume...

 

Stress echocardiography is a valuable tool in diagnosing and managing heart failure, revealing subclinical impairments and aiding in risk assessment, particularly for valvular, ischemic, and non-ischemic cardiac conditions.

  • Saved
ADA 2025 Highlights: Obesity Therapies, Islet Cell Advances, and Oral GLP-1 Outcomes in T2D

At ADA 2025, Dr. Mark Atkinson (University of Florida Diabetes Institute) highlighted the systemic benefits of obesity-targeted therapies, including cardiometabolic and cognitive improvements, while noting concerns about implementation and potential muscle loss. Emerging advances in stem cell–derived islet transplantation for type 1 diabetes show promise in reducing insulin dependence. Dr. John Buse (University of North Carolina) presented SOUL trial data indicating that oral GLP-1 receptor agonist therapy reduced major adverse cardiovascular events—CV death, nonfatal MI, or stroke—by 14%, with additional reductions in limb complications in high-risk patients with type 2 diabetes.